APRE - Aprea Therapeutics GAAP EPS of -$0.12 misses by $0.03
- Aprea Therapeutics press release ( NASDAQ: APRE ): Q3 GAAP EPS of -$0.12 misses by $0.03 .
- As of September 30, 2022, the Company had $33.1 million of cash and cash equivalents compared to $53.1 million of cash and cash equivalents as of December 31, 2021.
For further details see:
Aprea Therapeutics GAAP EPS of -$0.12 misses by $0.03